This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
Subjects voluntarily participate in this study and have signed informed consent.
Male or female subjects between the ages of 18 and 75 (including the threshold) at the time of signing the ICF.
History of plaque psoriasis ≥6 months at baseline.
Subjects need to receive systemic therapy and/or phototherapy.
The diagnosis was non-plaque psoriasis.
Subjects with concurrent skin diseases that the investigator believes would interfere with the study assessments.
Presence of infection or immune-related disease.
Subjects with a history of TB or at risk for TB.